The largest U.S. drugstore chain CVS has stopped selling the drug Zantac and generics (analogues) due to concerns that they may contain a substance that can cause cancer.
As reported in CVS, they are officially suspend sales of Zantac and other drugs containing ranitidine, until further notice.
Ranitidine is used to treat:
- of relapse of gastric ulcer and duodenal ulcer;
- reflux esophagitis, and erosive esophagitis;
- syndrome zollingerellison;
- prevention of recurrent bleeding from upper gastrointestinal tract;
- prevention of aspiration of gastric juice during operations under General anesthesia (Mendelson’s syndrome).
Earlier this month, Management on control over products and medicines USA (FDA) said that some ranitidine-containing drugs that reduce acidity and heartburn, including the well-known under the trademark Zantac contain low levels of impurities that can cause cancer.
Narozeninovy the impurity is known as N-nitrosodimethylamine, or NDMA, has been classified as a probable carcinogen to humans based on laboratory studies, and this is not the first time she discovered in conventional medicine.
Since last year, the FDA deals with the study of NDMA and other contaminants in drugs from blood pressure and heart failure, are known as blockers of receptors of angiotensin, or ARBS.
The FDA found “unacceptable” levels of nitrosamines in some of these common drugs containing valsartan.
A study published last year in the medical journal BMJ, revealed “significantly increased risk of cancer” among consumers of the drug valsartan, “contaminated” NDMA. However, this study also noted that it is necessary to study long-term cancer risk.
According to the CVS, customers who have already purchased Zantac or its analogues, can return them to the pharmacy, the purchase price will be reimbursed.